---
{"dg-publish":true,"permalink":"/updating-asma-a-partir-de-2022/"}
---


>[!info] **Understanding the Current Biologics in Asthma Treatment: review** (D. Imanirad, Semin Respir Crit Care Med 2022)
>In this review article, the authors summarize the current use of biologics for the treatment of patients with asthma. They review the current understanding of different disease phenotypes and endotypes and the pathophysiology of different endotypes. They then describe the currently approved biologics and considerations for choosing the appropriate ones for specific patients.

| Biológico              | *Target*                                    | Indicação                      | Dose                                                                | Outras patologias                                                      |     |
| ---------------------- | ------------------------------------------- | ------------------------------ | ------------------------------------------------------------------- | ---------------------------------------------------------------------- |:---:|
| Omalizumab (Xolair)    | IgE, Mastócitos                             | >6 anos, IgE 30-1500           | 150-375 mg SC cada 2 a 4 semanas                                    | Urticaria e Polipose nasal                                             |     |
| Mepolizumab (Nucala)   | IL-5                                        | >12 anos, >150-300 eosinófilos | 100mg SC cada 4 semanas                                             | Sindromes hipereosinófilicos, rinossinusite crónica com polipose nasal |     |
| Relizumab (Cinqair)    | IL-5                                        | >18 anos, > 400 eosinófilos    | 3mg/kg EV cada 4 semanas                                            | ----                                                                   |     |
| Benralizumab (Fasenra) | receptor de IL-5                            | >12 anos, >300 eosinófilos     | 30mg SC cada 4 semanas e posteriormente cada 8 semanas              |                                                                        |     |
| Dupilumab (Dupixent)   | Receptor de IL-4 que também reduz IL-13     | >12 anos com asma eosinofílica | 400-600 mg SC (load phase) e posteriormente 300mg SC cada 2 semanas | Dermatite atópica, Rinossinusite com polipose nasal                    |     |
| Tezepelumab            | TSLP (serve para asma com pouca inflamação) | Nao aprovado pela FDA          | 210 mg SC cada 4 semanas                                            | ----                                                                   |     |

